Streetbeat News

Earnings

APG

APi Group Corporation (APG) reported Q4 adjusted earnings per share (EPS) of $0.44, surpassing the consensus estimate of $0.43 by 2.33% and marking a 22.22% increase from the previous year. However, their quarterly sales of $1.76 billion slightly missed the estimate by 0.06%, though it represents a 3.29% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:32 pm

TPB

Turning Point Brands (NYSE:TPB) reported Q4 2023 adjusted EPS of $0.79, surpassing the $0.68 estimate, with sales of $97.12M exceeding the $90.11M forecast. This represents a 6.07% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:32 pm

PAYO

Payoneer Global (NASDAQ:PAYO) reported Q4 2023 earnings of $0.07 per share, surpassing the $0.05 estimate, with sales of $224.32M exceeding the $221.42M estimate, marking a 22.21% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:32 pm

EME

EMCOR Group (NYSE:EME) reported Q4 earnings of $4.47 per share, surpassing the $3.55 estimate, a 69.96% increase from last year. Sales reached $3.44B, beating the $3.36B estimate, marking a 16.58% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:32 pm

HLLY

Holley (NYSE:HLLY) reported Q4 sales of $155.71M, surpassing the analyst consensus estimate of $153.37M by 1.52% and marking a 1.00% increase from the previous year's sales of $154.16M.

Portfolio Pulse from saritha@benzinga.com

February 28, 2024 | 12:32 pm

KNSA

Kiniksa Pharmaceuticals, Ltd. (KNSA) projects its 2024 net product revenue for ARCALYST to be between $360M-$380M. Additionally, the company anticipates its current cash, cash equivalents, and short-term investments will sustain its operating plan until at least 2027.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:31 pm

TJX

TJX Companies reported Q4 2024 earnings per share of $1.12, meeting analyst expectations, and sales of $16.40 billion, exceeding the $16.21 billion estimate. This represents a 12.95% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:31 pm

KNSA

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported Q4 earnings of $0.35 per share, surpassing the $(0.14) estimate, marking a 350% beat and a 483.33% increase from last year's $0.06. Sales reached $83.39M, exceeding the $72.02M estimate by 15.79% and showing a 34.76% increase from the previous year.

Portfolio Pulse from Happy Mohamed

February 28, 2024 | 12:31 pm

LTH

Life Time Group (LTH) projects its 2024 revenue to be between $2.46B and $2.5B, aligning with the $2.46B consensus. The company also forecasts an adjusted EBITDA of $595M to $610M. These projections represent an approximate 11.9% increase in revenue and a 12.2% increase in adjusted EBITDA from 2023. Additionally, LTH aims to reduce its net debt leverage ratio to 3.0x by the end of 2024, become free cash flow positive in Q2 2024, open 9-10 new centers, and expects to leverage net operating loss carryforwards from the COVID-19 pandemic to offset a significant portion of its 2024 cash taxes.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:20 pm

LTH

Life Time Group (LTH) projects Q1 2024 revenue to be between $585M-$595M, surpassing the consensus estimate of $572.86M. The company also expects net income to range from $29M-$32M. These forecasts represent significant increases over the previous year, with revenue, net income, and adjusted EBITDA expected to grow by 15.5%, 10.9%, and 19.9% respectively.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:19 pm